CN100469767C - 联哌啶衍生物及其作为趋化因子受体抑制剂的用途 - Google Patents

联哌啶衍生物及其作为趋化因子受体抑制剂的用途 Download PDF

Info

Publication number
CN100469767C
CN100469767C CNB028079507A CN02807950A CN100469767C CN 100469767 C CN100469767 C CN 100469767C CN B028079507 A CNB028079507 A CN B028079507A CN 02807950 A CN02807950 A CN 02807950A CN 100469767 C CN100469767 C CN 100469767C
Authority
CN
China
Prior art keywords
compound
formula
phenyl
replaces
randomly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028079507A
Other languages
English (en)
Chinese (zh)
Other versions
CN1501915A (zh
Inventor
R·阿尔贝特
C·布伦斯
F·农宁格
M·施特赖夫
G·托马
H-G·策尔韦斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1501915A publication Critical patent/CN1501915A/zh
Application granted granted Critical
Publication of CN100469767C publication Critical patent/CN100469767C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
CNB028079507A 2001-04-09 2002-04-08 联哌啶衍生物及其作为趋化因子受体抑制剂的用途 Expired - Fee Related CN100469767C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0108876.4 2001-04-09
GBGB0108876.4A GB0108876D0 (en) 2001-04-09 2001-04-09 Organic Compounds

Publications (2)

Publication Number Publication Date
CN1501915A CN1501915A (zh) 2004-06-02
CN100469767C true CN100469767C (zh) 2009-03-18

Family

ID=9912541

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028079507A Expired - Fee Related CN100469767C (zh) 2001-04-09 2002-04-08 联哌啶衍生物及其作为趋化因子受体抑制剂的用途

Country Status (27)

Country Link
US (1) US20040142920A1 (enExample)
EP (1) EP1379504B1 (enExample)
JP (1) JP4366079B2 (enExample)
KR (1) KR100616039B1 (enExample)
CN (1) CN100469767C (enExample)
AR (1) AR035815A1 (enExample)
AT (1) ATE446950T1 (enExample)
AU (1) AU2002302511B2 (enExample)
BR (1) BR0208741A (enExample)
CA (1) CA2439241C (enExample)
CZ (1) CZ20032723A3 (enExample)
DE (1) DE60234167D1 (enExample)
EC (1) ECSP034765A (enExample)
ES (1) ES2335393T3 (enExample)
GB (1) GB0108876D0 (enExample)
HU (1) HUP0303724A3 (enExample)
IL (1) IL157428A0 (enExample)
MX (1) MXPA03009220A (enExample)
NO (1) NO20034324D0 (enExample)
NZ (1) NZ528712A (enExample)
PE (1) PE20021004A1 (enExample)
PL (1) PL363011A1 (enExample)
PT (1) PT1379504E (enExample)
RU (1) RU2296751C2 (enExample)
SK (1) SK12422003A3 (enExample)
WO (1) WO2002081449A1 (enExample)
ZA (1) ZA200306432B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1404667T3 (da) 2001-07-02 2006-07-10 Astrazeneca Ab Piperidinderivater, der er anvendelige som modulatorer af chemokinreceptoraktivitet
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AR036366A1 (es) 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0202838D0 (sv) * 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
ATE334680T1 (de) * 2002-10-04 2006-08-15 Ucb Sa 4-aminopiperidin-derivate, verfahren zur herstellung und ihre verwendung als arzneimittel
GB0223223D0 (en) 2002-10-07 2002-11-13 Novartis Ag Organic compounds
DE60324014D1 (de) * 2002-12-13 2008-11-20 Smithkline Beecham Corp Heterocyclische verbindungen alsccr5-antagonisten
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
EP1616862A4 (en) * 2003-04-18 2008-07-16 Ono Pharmaceutical Co HETEROCYCLIC NITROGEN COMPOUND AND USE THEREOF
FR2854158B1 (fr) * 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
WO2004113323A1 (en) * 2003-06-13 2004-12-29 Schering Aktiengesellschaft Quinolyl amide derivatives as ccr-5 antagonists
CA2544377A1 (en) * 2003-11-03 2005-05-12 Schering Corporation Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
US7498346B2 (en) * 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
WO2006077499A1 (en) * 2005-01-20 2006-07-27 Pfizer Limited Chemical compounds
KR20080037655A (ko) 2005-07-21 2008-04-30 아스트라제네카 아베 신규 피페리딘 유도체
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
JP2010512340A (ja) * 2006-12-06 2010-04-22 ジェンザイム・コーポレーション ケモカイン受容体結合性化合物
US8410144B2 (en) 2009-03-31 2013-04-02 Arqule, Inc. Substituted indolo-pyridinone compounds
EP3597761B1 (en) 2011-03-09 2025-05-07 Richard G. Pestell Prostate cancer cell lines, gene signatures and uses thereof
EP2861302A4 (en) * 2012-05-14 2016-08-24 Prostagene Llc USE OF CCR5 MODULATORS IN THE TREATMENT OF CANCER
JP2017503783A (ja) 2013-12-19 2017-02-02 バイエル ファーマ アクチエンゲゼルシャフト アドレナリン受容体アルファ２ｃ拮抗薬としての置換されたビピペリジニル誘導体
JOP20200052A1 (ar) 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
JP2017503778A (ja) 2013-12-19 2017-02-02 バイエル ファーマ アクチエンゲゼルシャフト アドレナリン受容体α２Ｃ拮抗薬としての置換されたビピペリジニル誘導体
EP3083593A1 (de) 2013-12-19 2016-10-26 Bayer Pharma Aktiengesellschaft Substituierte piperidinyl-tetrahydrochinoline

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19643331A1 (de) * 1996-10-21 1998-04-23 Thomae Gmbh Dr K 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676054B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
TW531537B (en) * 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5952349A (en) * 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
ES2314305T3 (es) * 1996-09-10 2009-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Aminoacidos modificados, medicamentos que contienen estos compuestos y procedimiento para su obtencion.
DE19637043A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Neue Aminoalkoholderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel und Reagenzien
EP1175402B1 (en) * 1999-05-04 2005-07-20 Schering Corporation Piperidine derivatives useful as ccr5 antagonists
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
ES2274793T3 (es) * 1999-06-11 2007-06-01 MERCK & CO., INC. Modulares n-ciclopentilicos de la actividad del receptor de la quimioquina.
CA2413418A1 (en) * 2000-06-21 2001-12-27 Joseph B. Santella Piperidine amides as modulators of chemokine receptor activity
EP1322628A2 (en) * 2000-09-14 2003-07-02 Schering Corporation Substituted urea neuropeptide y y5 receptor antagonists
AR036366A1 (es) * 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0223223D0 (en) * 2002-10-07 2002-11-13 Novartis Ag Organic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19643331A1 (de) * 1996-10-21 1998-04-23 Thomae Gmbh Dr K 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
IL157428A0 (en) 2004-03-28
EP1379504B1 (en) 2009-10-28
MXPA03009220A (es) 2004-01-29
CA2439241A1 (en) 2002-10-17
CN1501915A (zh) 2004-06-02
GB0108876D0 (en) 2001-05-30
ATE446950T1 (de) 2009-11-15
PE20021004A1 (es) 2003-01-03
CA2439241C (en) 2010-06-08
NZ528712A (en) 2005-07-29
AR035815A1 (es) 2004-07-14
HUP0303724A2 (hu) 2004-03-01
ECSP034765A (es) 2003-10-28
KR100616039B1 (ko) 2006-08-28
HUP0303724A3 (en) 2007-09-28
US20040142920A1 (en) 2004-07-22
ES2335393T3 (es) 2010-03-26
KR20030087066A (ko) 2003-11-12
NO20034324L (no) 2003-09-26
NO20034324D0 (no) 2003-09-26
WO2002081449A1 (en) 2002-10-17
JP2004525174A (ja) 2004-08-19
RU2003130642A (ru) 2005-04-10
JP4366079B2 (ja) 2009-11-18
BR0208741A (pt) 2004-06-22
DE60234167D1 (de) 2009-12-10
CZ20032723A3 (cs) 2003-12-17
SK12422003A3 (sk) 2004-05-04
PL363011A1 (en) 2004-11-15
RU2296751C2 (ru) 2007-04-10
EP1379504A1 (en) 2004-01-14
AU2002302511B2 (en) 2005-08-04
ZA200306432B (en) 2004-06-04
PT1379504E (pt) 2010-01-04

Similar Documents

Publication Publication Date Title
CN100469767C (zh) 联哌啶衍生物及其作为趋化因子受体抑制剂的用途
AU2002302511A1 (en) Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
IL196059A (en) Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
CA2172377A1 (en) Novel 4-piperidinyl substituted lactames as neurokinin 2-receptor antagonists for the treatment of asthma
WO1996002503A1 (en) Novel compound having platelet aggregation inhibitor effect
WO2002000259A1 (en) Remedial agent for anxiety neurosis or depression and piperazine derivative
HUP0402567A2 (hu) Piperidinszármazékok és alkalmazásuk kemokin receptor (különösen CCR5) aktivitás modulátoraiként
US6225324B1 (en) Antidepressant heterocyclic compounds
EP1256575B1 (en) Phenoxyalkylamine derivatives useful as opioid delta receptor agonists
US20080249111A1 (en) Piperdine Derivatives as CCR5 Inhibitors
JPWO2005030722A1 (ja) Ｎ−置換−ｎ−（４−ピペリジニル）アミド誘導体
JPWO1996002503A1 (ja) 血小板凝集阻害作用を有する新規化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090318

Termination date: 20110408